Tranexamic Acid Use in Intracranial Hemorrhage

Evidence by Type of Intracranial Hemorrhage

The American College of Cardiology and other guideline societies suggest that TXA shows no significant impact on mortality (RR 1.02, 95% CI 0.88-1.19) or poor functional outcomes (RR 0.98, 95% CI 0.93-1.04) in non-traumatic ICH, based on moderate evidence 1, 2
TXA reduces the risk of rebleeding in SAH (RR 0.6, 95% CI 0.44-0.8) but increases the risk of cerebral ischemia/stroke (RR 1.29, 95% CI 1.01-1.67), according to the American Heart Association 3, 1

Early administration (within 3 hours of symptom onset, ideally within 1 hour) is essential if TXA is to be used, as recommended by the American College of Emergency Physicians 4, 5, 6
Patient selection is crucial - those with very large hemorrhages are unlikely to benefit as reduction of further bleeding would have minimal impact, based on evidence from the Journal of the American Medical Association 4, 5, 6

TXA has not shown significant increases in thromboembolic events across studies of intracranial hemorrhage, according to the American Stroke Association 1
The increased risk of cerebral ischemia in SAH patients is a notable exception to the otherwise favorable safety profile, as reported by the Neurocritical Care Society 3, 1

Ongoing trials are investigating TXA in specific contexts, including treatment of ICH in patients on direct oral anticoagulants, as noted by the International Society on Thrombosis and Haemostasis 4, 5, 6

The American Heart Association/American Stroke Association guidelines (2022) do not provide a specific recommendation for tranexamic acid in spontaneous ICH, noting that early trials showed neither benefit nor safety concerns 7
The European Stroke Organisation (2014) concluded that a small RCT of tranexamic acid in ICH demonstrated neither benefit nor safety concerns, and recommended further trials 8
Neither major guideline body recommends routine use of tranexamic acid for spontaneous ICH, including hypertensive ICH, outside of ongoing clinical trials 7, 8

Tranexamic acid is contraindicated in active disseminated intravascular coagulation, and should be used with caution in patients with massive hematuria or renal insufficiency 7, 8

The American Heart Association/American Stroke Association and the European Stroke Organisation do not support routine use of tranexamic acid for spontaneous ICH, including hypertensive ICH, as it reduces hematoma expansion but does not improve functional outcomes or mortality 9

In traumatic brain injury, CRASH-3 showed potential benefit in mild-to-moderate injury when given within 3 hours (RR 0.78, 95% CI 0.64-0.95) 9
Administration of tranexamic acid must occur within 3 hours of symptom onset, ideally within 1 hour, to be effective, with a standard dosing of 1g IV loading dose over 10 minutes, followed by 1g infusion over 8 hours 9

Many factors beyond hematoma expansion determine clinical outcome after intracerebral hemorrhage, including baseline hemorrhage volume, level of consciousness, intraventricular hemorrhage presence, age, and comorbidities 10
Do not use TXA based solely on radiographic endpoints, as hematoma expansion reduction does not equal improved patient outcomes in non-traumatic hemorrhage 10